Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Evotec AG. (3/28/17). "Press Release: Evotec Fiscal Year Results 2016. Leading Innovation Efficiency and First-in-class Drug Discovery". Hamburg.

Organisations Organisation Evotec AG (FSE: EVT, TecDAX)
  Group Evotec (Group)
  Organisation 2 Topas Therapeutics GmbH
Products Product drug discovery services
  Product 2 EVT 201
Index terms Index term Cyprotex–Evotec: investment, 201610–201612 acquisition £55.7m=€66.3m in cash for all 26.1m shares + funding of all debt
  Index term 2 Evotec–Novo Group: investment, 201702 strategic investment of €90.3m 13.15m new Evotec shares at €6.87/share resulting in 8.9% ownership by Novo A/S
     


   
Record changed: 2017-04-19

Advertisement

Picture Lipotype Lipidomics Drug Biomarker Discovery iito 600x60px

More documents for Evotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top